MiR-31-3p do not predict anti-EGFR efficacy in first-line therapy of RAS wild-type metastatic right-sided colon cancer

Emeric Boisteau,Alexandra Lespagnol,Marie De Tayrac,Sébastien Corre,Anthony Perrot,Nathalie Rioux-Leclercq,Séverine Martin-Lannerée,Pascal Artru, Philippe Chalabreysse,Pierre-Guillaume Poureau,Laurent Doucet,Dahna Coupez,Jaafar Bennouna,Céline Bossard,Romain Coriat,Frédéric Beuvon,Lucile Bauguion, François Leclair,Romain Chautard,Thierry Lecomte

Clinics and Research in Hepatology and Gastroenterology（2022）

引用 1|浏览20

暂无评分

摘要

•miR-31-3p expression is predictive of anti-EGFR efficacy in mCRC.•Primary tumor side is prognostic and predictive of anti-EGFR efficacy in mCRC.•In right-sided RAS-wt mCRC, miR-31-3p expression do not predict anti-EGFR efficacy and bevacizumab is the targeted therapy of choice whatever miR-31-3p expression level.

查看译文

关键词

Colorectal cancer,Metastasis,Biomarker,miR-31-3p,anti-EGFR mAb,Bevacizumab

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要